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Mutations of two tumour suppressor genes, BRCA1 and BRCA2,
have been identified in some cases of familial and early onset
breast cancer (Miki et al, 1994; Wooster et al, 1995). These muta-
tions, however, account for no more than about 5% of total cases
of female breast cancer. Male breast cancer is rare (approximately
1% of all cases of breast cancer) and therefore less is known about
the genetic influences in its development. Male breast cancer has
been linked to mutations of the BRCA2 gene in some cases. The
frequency of mutations in the series studied varies widely, from
4% to 40% (Thorlacius et al, 1996; Friedman et al, 1997).
It has been suggested there may be other genetic factors that
confer a relatively low absolute risk to the individual, but
potentially could result in a substantial number of cases in the
whole population (Feigelson et al, 1996). The CYP17 gene on
chromosome 10 codes for the cytochrome P450c17a enzyme
that catalyses steroid 17a-hydroxylase and 17,20-lyase activities
(Picado-Leonard, 1987). It is therefore a key regulator in the
synthesis of androgens and oestrogens from their steroid precur-
sors (Brentano et al, 1990). A polymorphic T to C substitution has
been described that creates an additional CCACC type promoter
site 34 bp upstream from the site of initiation of translation (Carey
et al, 1994). It is thought that the additional promoter site may
increase the rate of transcription of the gene and thereby increase
enzyme activity. Serum oestradiol levels are higher in women
hetero- and homozygous for the C allele of the CYP17 gene
(Feigelson et al, 1998). One study found that the C allele was
associated with an increased risk of advanced breast cancer
(Feigelson et al, 1997). A larger and more recent study, however,
found no such association (Dunning et al, 1998). Male breast
cancer is known to be associated with conditions, for example
Klinefelter￿s syndrome, that result in increased levels of serum
oestrogens (Jackson et al, 1965). Mutation of the androgen
receptor gene has also been reported in a few cases of male breast
cancer (Wooster et al, 1992; Lobaccaro et al, 1993). This mutation
results in a change in the androgen—oestrogen balance (low
levels of androgens, increased levels of oestrogens). Given that
the C allele of the CYP17 gene is associated with increased serum
oestradiol levels, then it could also be implicated in the develop-
ment of male breast cancer. The aim of this study was to test this
hypothesis.
METHODS
Case and control population selection
Male cases were taken from a consecutive series of 76 male breast
cancer patients treated in the South East of Scotland between 1974
and 1998. These patients ranged in age from 26 to 91 years at the
time of diagnosis. Living patients were contacted through their
General Practitioners. Initial contact was by telephone where
possible. Peripheral blood samples (10 ml) were obtained from 24
living male breast cancer patients. Written informed consent was
obtained in all cases. Archival wax-embedded tissue sections were
obtained for 39 deceased patients. DNA previously extracted from
a blood sample and stored was available for one of the deceased
patients. Two patients declined to take part in the study. Archival
specimens were not available in ten cases. Female cases were a
consecutive group of 39 patients with early onset (age < 50 years)
breast cancer referred to the Edinburgh Breast Unit, Western
General Hospital, Edinburgh between 1987 and 1990.
Male and female control DNA samples were extracted from
blood donations to the Edinburgh and South East Scotland Blood
Transfusion service, from placental tissue and blood donations
to the School of Biological and Medical Sciences, University of
St Andrews, and from a small number of tonsillectomy specimens
provided by the Department of ENT Surgery, City Hospital,
Edinburgh. We believe that these samples are representative of
the population within the South East Scotland region.
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DNA extraction was from whole blood by standard phenol—
chloroform extraction. DNA extraction from wax-embedded
tissue was from 10-mm sections incubated at 55°C with a lysis
buffer and proteinase K.
The following primers were designed for polymerase chain
reaction (PCR): CYP17S-F, 5¢-CAAAAGTCAAGGTGAA-
GATCAG-3¢; CYP17S-R, 5¢-TAGGGTAAGCAGCAAGAGAG-3¢.
These generate PCR fragments 150 base pairs in length, including
the polymorphic site. PCR reactions were performed in 50-ml
aliquots, each containing 1 3 buffer, 2 mM magnesium chloride,
100 mM deoxynucleoside triphosphates, 100 pmol of each primer,
1 unit of Taq polymerase (Life TechnologiesTM) and approximately
100 ng DNA. The amplification was performed using an
OmniGene thermal cycler (Hybaid, UK) under the following
conditions: initial denaturation at 94°C for 3 min; amplification
for 38 cycles, with denaturation at 94°C for 45 s, annealing at
56°C for 45 s and extension at 72°C for 45 s; final extension at
72°C for 10 min. The PCR products were digested with MspA1
(Promega, Madison, WI, USA) for 90 min at 37°C. The products
were separated by electrophoresis on a 4% agarose gel, staining
with ethidium bromide and identified from photographs of the gel
under ultraviolet illumination.
Data analysis
The association between the C allele of the CYP17 gene and breast
cancer in the male and female subjects and controls was analysed
using c2 tests.
RESULTS
The results showing the genotyping of the cases and controls are
shown in Table 1. The results show that a C allele is found signifi-
cantly more frequently in male breast cancer patients than in male
controls (c2 = 4.308, 1 d.f., P = 0.038). The odds ratio (OR) for the
risk of a male with a C allele developing breast cancer is calculated
as 2.10 (95% confidence interval (CI) 1.04—4.27). There were no
significant differences between female breast cancer patients and
female controls (c2 = 1.895, 1 d.f., P = 0.169; OR = 0.56, 95%
CI 0.25—1.28). The distribution of alleles in both control groups is
in Hardy—Weinberg equilibrium (Table 2).
DISCUSSION
To our knowledge, this is the first study that attempts to evaluate
the possible role of a polymorphism of the CYP17 gene in the
development of male breast cancer. We have found that the poly-
morphic T to C substitution within the CYP17 gene occurs signifi-
cantly more frequently in male breast cancer patients than in male
controls. These results are consistent with other reports that there
may be a hormonal contribution to the development of male breast
cancer (Jackson et al, 1965; Lobaccaro et al, 1993; Wooster et al,
1992). We have also studied a small group of female breast cancer
patients from the same geographical region. We found no associa-
tion between the presence of a C allele of the CYP17 gene and
female breast cancer. The first study that looked at this polymor-
phism in female breast cancer patients (Feigelson et al, 1997),
found a significant association only after sub-selecting those
patients that presented with advanced disease. The second, and
much larger, study (Dunning et al, 1998) did find a small increase
in the risk of breast cancer associated with the C allele, but this
increase was not statistically significant. It is possible that the T to
C polymorphism in the CYP17 gene is associated with higher
levels of serum oestrogens, but that because the endogenous
oestrogen level is higher in females than in males, further increase
does not have a significant effect. The association between an
increase in the levels of serum oestrogens and the development of
breast cancer may therefore be detectable only in males, or
perhaps as previously suggested (Dunning et al, 1998), among
post-menopausal females.
Further studies of this type are required, specifically to test for
any association between the polymorphism of the CYP17 gene
and levels of serum oestrogens in males.
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Table 1 CYP17 genotype frequencies among breast cancer patients and controls
Males Females
Genotype Cases (n = 64) Controls (n = 81) Cases (n = 39) Controls (n = 58)
TT 17 (26.6%) 35 (43.2%) 21 (53.8%) 23 (39.7%)
TC 42 (65.6%) 39 (48.1%) 13 (33.3%) 28 (48.3%)
CC 5 (7.8%) 7 (8.6%) 5 (12.8%) 7 (12.1%)
TC/CC 47 (73.4%) 46 (56.8%) 18 (46.2%) 35 (60.3%)
Table 2 CYP17 genotype frequencies in controls and expected frequencies under Hardy–Weinberg equilibrium
Male controls Female controls
Observed Expected Observed Expected
TT 35 36.7 23 23.6
TC 39 35.7 28 26.8
CC 7 8.67 7 7.60
(c2 = 0.705, 2 d.f., P = 0.703) (c2 = 0.116, 2 d.f., P = 0.943)ACKNOWLEDGEMENTS
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